BioStem (BSEM) Director Steven Sonenreich Converts RSUs to Shares

What Happened
Steven D. Sonenreich, a director of BioStem Technologies, had 7,671 restricted stock units (RSUs) vest and convert into 7,671 shares on August 27, 2026. The Form 4 reports the derivative conversion under transaction code M (exercise/conversion of a derivative) with an acquisition price of $0.00 and reported value $0.00 — this was a vesting/settlement event rather than a market purchase or sale.

Key Details

• Transaction date: 2026-08-27 (filed 2026-08-28) — filing appears timely.
• Reported transactions: 7,671 shares acquired via conversion (code M) at $0.00; 7,671 shares also reported as disposed at $0.00 in the same filing.
• Footnotes: F1 — each RSU represents a contingent right to one share; F2 — these RSUs vested on August 27, 2026.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Exhibit/remark: Exhibit 24 — Power of Attorney.

Context
Conversion of RSUs into shares is a common compensation settlement when awards vest; it is not the same as an insider buying or selling stock in the market. The Form shows both acquisition and disposition of the same number of shares at $0.00, consistent with a vest/settle event reported as a derivative conversion. This filing does not, by itself, indicate a bullish or bearish trade by the insider.